Xencor Inc (XNCR)
Cash conversion cycle
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | — | — | — | — | — |
| Days of sales outstanding (DSO) | days | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — |
| Cash conversion cycle | days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Cash conversion cycle = DOH + DSO – Number of days of payables
= — + — – —
= 0.00
Based on the data provided, Xencor Inc's cash conversion cycle has consistently been 0.00 days from December 31, 2020, through December 31, 2024. A cash conversion cycle of 0.00 days indicates that Xencor Inc is efficiently managing its cash flow and operating cycle. This suggests that the company is able to quickly convert its inventory into sales, collect receivables promptly, and pay its payables in a timely manner. Overall, a consistently low or zero cash conversion cycle reflects strong working capital management and efficient financial operations at Xencor Inc.
Peer comparison
Dec 31, 2024
Company name
Symbol
Cash conversion cycle
Xencor Inc
XNCR
0.00
Abbott Laboratories
ABT
120.86
AbbVie Inc
ABBV
90.28
ACADIA Pharmaceuticals Inc
ACAD
97.89
Alkermes Plc
ALKS
146.34
Amphastar P
AMPH
193.56
ANI Pharmaceuticals Inc
ANIP
199.53
Arcus Biosciences Inc
RCUS
-36.73
Biomarin Pharmaceutical Inc
BMRN
860.14
Bristol-Myers Squibb Company
BMY
69.21
Catalyst Pharmaceuticals Inc
CPRX
103.60